Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President
Q32 Bio Inc. (QTTB) reported that its CFO and President, Lee Kalowski, was granted 53,250 restricted stock units (RSUs) as part of his compensation. This award, valued at $0.00 per share, is not an open-market purchase. The RSUs will vest in four equal installments, beginning six months after the February 24, 2026 grant date, and subsequently at 12, 24, and 36 months, increasing Kalowski's direct holdings to 89,193 shares.
MAR 11·AlphaStreet→
Q32 Bio Inc. (QTTB) Reports Q4 Earnings
Q32 Bio Inc. (QTTB) announced its Q4 2025 earnings, reporting $4.58 per share and total revenue of $53.7 million. The clinical-stage biotechnology company specializes in developing novel biologics for autoimmune and inflammatory diseases, with its lead candidate, Bempikibart, targeting conditions like atopic dermatitis and alopecia areata.
AUG 6·Motley Fool→
Q32 Bio ( QTTB ) Q2 Loss Drops 45%
Q32 Bio ( NASDAQ:QTTB ) , a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, released its second quarter results on August 6, 2025. The main news was a notably reduced GAAP net loss of $0.78 per share.
